MOTS-C Nasal Spray Dosage: What Research Actually Shows

There is no clinically established MOTS-C nasal spray dosage. In research-vendor protocols and community reports, intranasal MOTS-C is usually described as 5 mg to 10 mg per day, often split into two doses, but those figures come from anecdotal use rather than controlled human trials. MOTS-C has never been tested in a published human study using a nasal spray, so any specific number should be treated as a discussion point with a qualified clinician, not a prescription.

MOTS-C is a mitochondrial-derived peptide, meaning it is encoded by DNA inside the mitochondria rather than the cell nucleus. Early laboratory work suggests it plays a role in metabolic regulation and how cells respond to exercise, which is why it has drawn attention in longevity and metabolic research circles.

What MOTS-C Is and Why People Research It

MOTS-C, short for mitochondrial open reading frame of the 12S rRNA-c, was identified in 2015 by researchers studying how mitochondria communicate with the rest of the cell. In animal and cell models, it has been linked to insulin sensitivity, AMPK activation, and exercise capacity.

Those findings are preliminary. Nearly all of the data comes from rodent models and in vitro work, and the peptide's behavior in humans is not well characterized. Whether MOTS-C levels decline with age is an open question that researchers continue to study.

Because MOTS-C is a peptide, it is fragile in the digestive tract, which is why injectable and intranasal routes dominate discussion. Oral capsules are widely considered ineffective for delivering intact peptides.

Reported MOTS-C Nasal Spray Dosage Ranges

Every number below comes from vendor guidance or user reports, not from peer-reviewed human trials. Treat the table as a map of what is being discussed online, not as medical guidance.

Injectable MOTS-C protocols in research settings usually sit at 5 mg to 10 mg per day, and intranasal versions tend to mirror or slightly exceed those figures. The reason for the higher intranasal numbers is bioavailability, which is covered below.

Typical cycle lengths discussed online range from 4 to 12 weeks, with breaks in between. No data supports one schedule over another.

How Intranasal Delivery Changes the Math

Intranasal absorption of peptides is generally lower than subcutaneous injection, because only a fraction of the dose crosses the nasal mucosa intact. As a result, most intranasal protocols compensate by using a larger nominal dose or by dividing it across both nostrils.

Enzymes in the nasal cavity can also break peptides down before they reach circulation. This is one reason results from intranasal use are harder to predict than injections, even when the label dose looks identical.

Converting milligrams to sprays

What matters is the concentration on the label, not the number of sprays. A typical nasal pump delivers roughly 0.05 to 0.1 mL per spray, so a 10 mg/mL solution gives about 0.5 to 1 mg per spray.

At that concentration, a 5 mg dose would require 5 to 10 sprays, which is impractical for most people. Always confirm the mg-per-spray figure before assuming an advertised dose is realistic.

How MOTS-C Compares With Other Intranasal Peptides

Dosing conventions vary enormously across research peptides, and comparing them side by side helps clarify why MOTS-C numbers look large. Metabolic compounds such as the aod-9604 nasal spray dosage are usually measured in micrograms or low milligrams, while sleep-focused options like the dsip nasal spray dosage sit in the microgram range as well.

Hormonal peptides follow their own logic: the kisspeptin-10 nasal spray dosage is far smaller than any MOTS-C protocol because kisspeptin acts on receptors at very low concentrations. The thymosin alpha 1 nasal spray dosage sits in the low milligram range, closer to MOTS-C, because it is a larger immune-modulating peptide.

Sexual-health research peptides are a separate case again, since the pt-141 nasal spray dosage for men is typically measured in micrograms to low milligrams per dose rather than per day. That variation is why copying a dose from one peptide to another is a common and serious mistake.

Practical Considerations Before Using a MOTS-C Nasal Spray

• Verify the concentration. Confirm mg per mL and mL per spray so you know how much you are actually delivering.
• Prime the pump. New bottles need a few priming sprays before they deliver a consistent volume.
• Alternate nostrils. Rotating sides may reduce local irritation.
• Store correctly. Most peptide solutions need refrigeration and protection from light.
• Keep a log. Track dose, timing, and any side effects so you have real data if you speak with a clinician.

Safety, Side Effects, and Legal Status

MOTS-C is not FDA-approved for human use in the United States. It is sold as a research chemical, which means it is not evaluated for sterility, purity, or safety in humans, and it is not a legal dietary supplement.

Reported side effects from intranasal peptide use are mostly local, including nasal irritation, dryness, and occasional headache. Systemic effects of MOTS-C in humans are essentially unknown because no human trials have been published.

Anyone considering a MOTS-C nasal spray should speak with a licensed healthcare professional first, especially people who are pregnant, take prescription medication, or manage a metabolic or autoimmune condition. Self-experimentation with unapproved peptides carries real risk, and a dose found online may have no basis in human data.

Bottom Line

There is no official MOTS-C nasal spray dosage, and the 5–10 mg per day figure circulating online comes from anecdotal reports rather than clinical evidence. Intranasal absorption is unpredictable, product concentrations vary widely, and MOTS-C remains unapproved for human use.

If you are researching intranasal peptides, treat every dose you see as unverified until you can trace it to a published human study. In the case of MOTS-C, that study does not yet exist.